衛教資訊
衛教單張
Health Education ResourcesEpirubicin 認識化療藥品Epirubicin
2024/1/22Epirubicin is classified as an anthracyline antibiotic. This medicine inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually cause cell death.
Eribulin 認識化療藥品Eribulin
2024/1/22Eribulin is a synthetic product derived from a natural substance found in a sea sponge. This medicine inhibits the function of microtubules for cell division, thus stopping cancer cells from separating into two new cells, eventually causing cell death.
Fludarabine 認識化療藥品Fludarabine
2024/1/22Fludarabine is classified as an anticancer antimetabolites. This drug inhibiting DNA polymerase that is essential for the replication of DNA and RNA.
Inotuzumab ozogamicin 認識化療藥品Inotuzumab
2024/1/22Besponsa® is an antibody-drug conjugate combining a cytotoxic agent called calicheamicin with a monoclonal antibody, which targets a protein called CD22 on the surface of B cells.
Ipilimumab 認識標靶藥品Ipilimumab
2024/1/22Ipilimumab is a monoclonal antibody that binds to CTLA-4 (human cytotoxic T lymphocyte-associated antigen 4) on T cells. By blocking CTLA-4, ipilimumab helps strengthen the immune system by promoting the function and growth of T cells, thereby enhancing the immune system against cancer cells.
Kadcyla 認識標靶藥品Kadcyla
2024/1/22Trastuzumab is a monoclonal antibody which targets the human epidermal growth factor receptor 2 (HER2) on cells. HER2 is found in large amounts on the surface of breast cancer cells, resulting in tumors growing more quickly. By attaching to the HER2 receptor, trastuzumab blocks HER2 from receiving growth signals, preventing further cancer growth and slowing cancer progression.
Melphalan 認識化療藥品Melphalan
2024/1/22Melphalan is an alkylating agent that exerts its anticancer activity by reacting with DNA and interfering with DNA replication and cell division. This stops the growth and spread of cancer cell in the body.
Nivolumab 認識標靶藥品Nivolumab
2024/1/22Nivolumab is a monoclonal antibody that binds to PD-1 (Programmed cell death protein 1) and blocks its interaction with PD-L1 (programmed cell death ligand 1).
Obinutuzumab 認識標靶藥品Obinutuzumab
2024/1/22Obinutuzumab is a monoclonal antibody that targets to a protein called CD20 on the surface of white blood cells known as B lymphocytes. When obinutuzumab attaches to the surface of these cells, the abnormal growth of the B lymphocytes is stopped.
Olaratumab 認識化療藥品Olaratumab
2024/1/22Olaratumab is a monoclonal antibody that binds to platelet-derived growth factor receptor-alpha (PDGFRα), which locates on the surface of cancer cells. This drug blocks the activation of PDGFRα, thus inhibiting cell proliferation and tumor growth.
統計數據
3064 篇
1915 篇
1226 篇